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De-diagnosing disease  
 
(763 words) 
 
I tried to placate an angry man in my clinic the other day but I wasn’t very successful. The 
problem wasn’t that he had to wait two weeks to get an appointment to see me, it was 
more profound.  
‘All I want to know, doctor’ said Mr Brown, ‘is do I or don’t I have a disease?’.  
A recent blood test suggested a diagnosis of pre-diabetes. Our practice systems had swung 
into action and Mr Brown was trying to deal with the emotional and practical consequences. 
My explanation that he didn’t have a disease as such, more that he was at risk of developing 
one, a kind of ‘pre-disease’ so to speak, didn’t seem to help.  
 
Making, or excluding, disease diagnoses is what GPs are trained to do. The underpinning 
methodology is straightforward, in principle at least; panels of experts are convened to 
develop guidelines which describe diagnostic criteria, based on the best possible research 
evidence. GPs then apply these criteria to individual patients.  
 
In practice, according to the authors of a recent article in BMJ Evidence Based Medicine 
(https://ebm.bmj.com/content/ebmed/early/2019/04/11/bmjebm-2018-111148.full.pdf),  
it’s a little more complicated. There is no international consensus governing the 
development of criteria for how a disease should be defined. In most countries the expert 
panels comprise mainly disease-focused specialists and their intent is to prevent disease by 
minimising the risk of under-diagnosis. Their decisions, the authors claim, are often 
influenced by the pharmaceutical industry. Insufficient attention is given to both the 
perspective of patients, in particular the unintended consequences of giving them a 
diagnostic label, and to the degree of influence exerted by vested interests. The problems 
are less marked in some countries as a consequence of systematic processes introduced by 
organisations such as the National Institute of Health and Care Excellence in England, but to 
some degree the challenge is a universal one. 
 The consequence is a growing number of people being labelled as ‘sick’ without clear 
evidence that they will benefit from being classified in this way. Too many people are being 
inappropriately diagnosed and unnecessarily treated for long term conditions such as 
hypertension, chronic kidney disease and gestational diabetes. Too many people are being 
given new diagnostic labels such as ‘pre-diabetes’ and ‘pre-osteoporosis’. Over-diagnosis is 
leading to harm for individual patients, purposeless increased workload for health 
professionals and inefficiencies for health systems. It’s a grim picture. 
 
The critique is provocative, powerful and engaging to those working in the frontline of 
healthcare. Disease-mongering feels like a real problem. 
 
So what should be done? The solutions are both simple and radical; new diagnostic labels 
should be more cautiously applied, perhaps even delayed to allow patients time to consider 
the benefits and risks of having a disease which might have few or no consequences for 
their long term health. Established diagnoses should be regularly reviewed. Responsibility 
for defining the entry criteria for a diseased state should shift. Medical specialists, who have 
a deep understanding of the pathogenesis, presentation and natural history of individual 
diseases, should have less influence over how diseases are defined. Medical generalists, 
who have a deep understanding of how diagnoses affect patients, their families and the 
health system, and have to deal with the consequences of diagnoses, should have greater 
influence. Patients, the public and citizen organisations should be central to the process.  
 
Rigid disease definitions should be replaced with ‘thresholds for discussion’ between 
doctors and patients. Doctors should make greater use of delayed diagnoses and should 
carry out regular and systematic diagnostic reviews, akin to medication reviews. Having the 
skill to de-diagnose disease should be a tool in the armory of every doctor. Generalist and 
specialist clinicians, patients and researchers should work collaboratively in order to fully 
tease out the risks as well as the benefits of diagnostic labelling and the process should be 
free from the influence of groups who have commercial interests.  
 
Fundamentally, the medical professional should not have a monopoly on the diagnostic 
process. The allocation of disease labels should take into account not only the statistical 
significance of research data underpinning guidelines, and the clinical significance of 
diseases as determined by doctors, but also the personal significance of disease as 
experienced by patients. Clinical diagnoses should be judged for their social consequences 
as well as being used as pathological labels and they should only be used when the benefits 
clearly outweigh the harms. The parting message of the paper is clear and dramatic: ‘the 
human person should no longer be treated as an ever expanding market place of diseases, 
benefiting professional and commercial interests while bringing great harm to those 
unnecessarily diagnosed’. 
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